4-oxo-27-TBDMS Withaferin A manufacturers
|
| | 4-oxo-27-TBDMS Withaferin A Basic information |
| Product Name: | 4-oxo-27-TBDMS Withaferin A | | Synonyms: | 4-oxo-27-TBDMS Withaferin A;Ergosta-2,24-dien-26-oic acid, 27-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6-epoxy-22-hydroxy-1,4-dioxo-, δ-lactone, (5β,6β,22R)-;(5β,6β,22R)-27-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5,6-epoxy-22-hydroxy-1,4-dioxo-ergosta-2,24-dien-26-oic acid, δ-lactone | | CAS: | 1214886-31-3 | | MF: | C34H50O6Si | | MW: | 582.85 | | EINECS: | | | Product Categories: | | | Mol File: | 1214886-31-3.mol |  |
| | 4-oxo-27-TBDMS Withaferin A Chemical Properties |
| Boiling point | 651.3±55.0 °C(Predicted) | | density | 1.14±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 5mg/mL; DMSO: 5mg/mL; DMSO:PBS (pH 7.2) (1:1): 0.5mg/mL |
| | 4-oxo-27-TBDMS Withaferin A Usage And Synthesis |
| Description | 4-oxo-27-TBDMS Withaferin A is a derivative of the steroidal lactone withaferin A that has anticancer activity.1 It is cytotoxic to A2780 ovarian cancer cells (IC50 = 17 μM) but not to carboplatin-resistant A2780 (A2780/CP70) cells (IC50 = >100 μM). It is selective for A2780 cells over non-cancerous ARPE19 cells (IC50 = 1,660 μM). 4-oxo-27-TBDMS Withaferin A induces DNA fragmentation in A2780 cells. | | Uses | 27-TBDMS-4-Dehydrowithaferin A, a withaferin A derivative, exhibits potent antiproliferative effects on the tumor cells.27-TBDMS-4-Dehydrowithaferin A induces tumor cells apoptosis. 27-TBDMS-4-Dehydrowithaferin A is a anticancer agent[1]. | | References | 1. Perestelo, N.R., Llanos, G.G., Reyes, C.P., et al. Expanding the chemical space of withaferin A by incorporating silicon to improve its clinical potential on human ovarian carcinoma cells J. Med. Chem. 62(9),4571-4585(2019). |
| | 4-oxo-27-TBDMS Withaferin A Preparation Products And Raw materials |
|